This article discusses the studies on radiotherapy of high-grade gliomas published between
January 1, 2022, and June 30, 2022, with special reference to their molecular biology basis …

Malignant gliomas are comprised of World Health Organization (WHO) Grade III and IV
gliomas. Median survival times for patients with Grade IV tumors, also known as …

Albeit the effort to develop targeted therapies for patients with high-grade gliomas (WHO
grades III and IV) is evidenced by hundreds of current clinical trials, radiation remains one of …

Effective treatment of glioblastoma multiforme (GBM) is complicated by multiple factors,
including the diffusely infiltrative nature of the disease, which limits complete surgical …

The optimal management of supratentorial low-grade glioma remains controversial, and
only limited definitive data is available to guide recommendations. Treatment decisions have …

Despite maximal surgical resection, postoperative radiotherapy and chemotherapy, the
median survival of patients with glioblastoma (GBM) is only approximately 10–15months …

Glioblastoma multiforme (GBM) is the most common malignant brain tumor that affects
approximately 17,000 patients annually. Clear survival advantages have been …

Glioblastoma, grade IV malignant glioma based on the World Health Organization
classification, is the most common primary brain tumor in adults. The average survival time …

Background Glioblastoma is the most common malignant brain tumor in human adults.
Despite several improvements in resective as well as adjuvant therapy over the last …

The expansion in understanding the molecular biology that characterizes cancer cells has
led to the rapid development of new agents to target important molecular pathways …